193 related articles for article (PubMed ID: 15383203)
61. Integrated PET-CT: evidence-based review of oncology indications.
Sachelarie I; Kerr K; Ghesani M; Blum RH
Oncology (Williston Park); 2005 Apr; 19(4):481-90; discussion 490-2, 495-6. PubMed ID: 15934517
[TBL] [Abstract][Full Text] [Related]
62. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma.
Pilling J; Dartnell JA; Lang-Lazdunski L
Thorac Cardiovasc Surg; 2010 Jun; 58(4):215-9. PubMed ID: 20514576
[TBL] [Abstract][Full Text] [Related]
63. Image analysis in patients with cancer studied with a combined PET and CT scanner.
Charron M; Beyer T; Bohnen NN; Kinahan PE; Dachille M; Jerin J; Nutt R; Meltzer CC; Villemagne V; Townsend DW
Clin Nucl Med; 2000 Nov; 25(11):905-10. PubMed ID: 11079589
[TBL] [Abstract][Full Text] [Related]
64. FDG PET and PET/CT for colorectal cancer.
Delbeke D; Martin WH
Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
[TBL] [Abstract][Full Text] [Related]
65. Utility of (18)F-FDG PET-CT in staging and restaging of patients with malignant salivary gland tumours: a single-institutional experience.
Sharma P; Jain TK; Singh H; Suman SK; Faizi NA; Kumar R; Bal C; Malhotra A; Kumar R
Nucl Med Commun; 2013 Mar; 34(3):211-9. PubMed ID: 23353886
[TBL] [Abstract][Full Text] [Related]
66. Improving the accuracy of target volume delineation by combined use of computed tomography, magnetic resonance imaging and positron emission tomography in head and neck carcinomas.
Chauhan D; Rawat S; Sharma MK; Ahlawat P; Pal M; Gupta G; Dewan A; Gupta M; Sharma S; Dodagoudar C; Pahuja A; Mitra S; Sharma SK
J Cancer Res Ther; 2015; 11(4):746-51. PubMed ID: 26881512
[TBL] [Abstract][Full Text] [Related]
67. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
[TBL] [Abstract][Full Text] [Related]
68. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging.
Choi JY; Lee KS; Kwon OJ; Shim YM; Baek CH; Park K; Lee KH; Kim BT
J Clin Oncol; 2005 Oct; 23(30):7654-9. PubMed ID: 16234527
[TBL] [Abstract][Full Text] [Related]
69. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
Ng SP; David S; Alamgeer M; Ganju V
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
[TBL] [Abstract][Full Text] [Related]
70. Metabolic imaging with FDG: a primer.
Delbeke D; Martin WH
Cancer J; 2004; 10(4):201-13. PubMed ID: 15383201
[TBL] [Abstract][Full Text] [Related]
71. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
72. The contribution of PET/CT to improved patient management.
Ell PJ
Br J Radiol; 2006 Jan; 79(937):32-6. PubMed ID: 16421402
[TBL] [Abstract][Full Text] [Related]
73. PET-CT fusion imaging in differentiating physiologic from pathologic FDG uptake.
Kostakoglu L; Hardoff R; Mirtcheva R; Goldsmith SJ
Radiographics; 2004; 24(5):1411-31. PubMed ID: 15371617
[TBL] [Abstract][Full Text] [Related]
74. Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality.
Iagaru A; Mittra E; Minamimoto R; Jamali M; Levin C; Quon A; Gold G; Herfkens R; Vasanawala S; Gambhir SS; Zaharchuk G
Clin Nucl Med; 2015 Jan; 40(1):1-8. PubMed ID: 25489952
[TBL] [Abstract][Full Text] [Related]
75. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
76. Positron emission tomography-computed tomography protocols for radiation therapy planning and therapy response assessment.
Shreve P; Swanston NM; Faasse T
Semin Ultrasound CT MR; 2010 Dec; 31(6):468-79. PubMed ID: 21147374
[TBL] [Abstract][Full Text] [Related]
77. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
78. Pulmonary lesion assessment: comparison of whole-body hybrid MR/PET and PET/CT imaging--pilot study.
Schwenzer NF; Schraml C; Müller M; Brendle C; Sauter A; Spengler W; Pfannenberg AC; Claussen CD; Schmidt H
Radiology; 2012 Aug; 264(2):551-8. PubMed ID: 22653189
[TBL] [Abstract][Full Text] [Related]
79. Retrospective digital image fusion of multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions--a prospective study with 104 patients.
Lemke AJ; Niehues SM; Hosten N; Amthauer H; Boehmig M; Stroszczynski C; Rohlfing T; Rosewicz S; Felix R
J Nucl Med; 2004 Aug; 45(8):1279-86. PubMed ID: 15299049
[TBL] [Abstract][Full Text] [Related]
80. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
